OCRA Ovarian Cancer Research Alliance Grant Number:813369 "Exploiting PARP-modulating enzymes in ovarian cancer therapy" (DSB.AD001.196)

Thematic area

Biomedical sciences

Project area

Structure responsible for the research project

Institute Experimental Endocrinology and Oncology "Gaetano Salvatore" (IEOS)

Project manager

LUCA PALAZZO
Phone number: 0817704795
Email: luca.palazzo@ieos.cnr.it

Abstract

The use of PARP inhibitors (PARPi) as maintenance therapy in women with ovarian cancer has resulted in significant prolongation of disease-free survival. However, many patients do not respond to PARPi and most of that do respond eventually develop PARPi resistance, thus raising important issues about promptly identifying patients most likely to derive benefit from PARP inhibition finding new and alternative therapies for PARPi-resistant ovarian cancers. In this project we propose to develop ARH3 and PARG proteins as biomarkers of response and resistance to PARPi whose levels and activities may allow stratification of patients who are most likely to benefit from PARP inhibition and those who will not. In addition, we aim to assess the ARH3 and PARG proteins as drug targets in a subclass of PARP-resistant ovarian cancers.

Goals

Complementary and Alternative Treatment Approaches, Technology Development and/or Marker Discovery

Start date of activity

01/01/2021

Keywords

parp, ovarian, cancer

Last update: 11/12/2023